Skip to main content
NCBI home page
Nucleus logoLink to Nucleus
. 2019 Mar 22;10(1):48–54. doi: 10.1080/19491034.2019.1589359

Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome

Magda R Hamczyk a,b,c, Vicente Andrés a,b,✉
PMCID: PMC6527384  PMID: 30900948

ABSTRACT

Lamin A, a product of the LMNA gene, is an essential nuclear envelope component in most differentiated cells. Mutations in LMNA have been linked to premature aging disorders, including Hutchinson-Gilford progeria syndrome (HGPS). HGPS is caused by progerin, an aberrant form of lamin A that leads to premature death, typically from the complications of atherosclerotic disease. A key characteristic of HGPS is a severe loss of vascular smooth muscle cells (VSMCs) in the arteries. Various mouse models of HGPS have been created, but few of them feature VSMC depletion and none develops atherosclerosis, the death-causing symptom of the disease in humans. We recently generated a mouse model that recapitulates most features of HGPS, including VSMC loss and accelerated atherosclerosis. Furthermore, by generating cell-type–specific HGPS mouse models, we have demonstrated a central role of VSMC loss in progerin-induced atherosclerosis and premature death.

KEYWORDS: Atherosclerosis, Hutchinson-Gilford progeria syndrome, lamin A, progerin, vascular smooth muscle cells

Characteristics of Hutchinson-Gilford progeria syndrome (HGPS)

HGPS is a premature aging disease that was first described by Jonathan Hutchinson in 1886 and Hastings Gilford in 1897 [1,2]. The prevalence of HGPS is about 1 in 20 million and it has no ethnic or gender bias [3]. Affected children appear normal at birth but progressively develop signs of premature aging, including alopecia, mottled and wrinkled skin, loss of body fat, and joint and bone abnormalities (osteoporosis and osteolysis of the mandible, phalanges, and clavicles) [3,4]. A key feature of HGPS is early-onset cardiovascular disease (CVD), leading to death typically from myocardial infarction or stroke at a mean age of 14.6 years [5]. While HGPS recapitulates most features of physiological aging, patients show no signs of neurodegenerative disease or cancer [3,5].

Atherosclerosis underlies death in most HGPS patients, and autopsy examination has revealed a wide variety of plaque phenotypes, ranging from early- to late-stage lesions [3,6]. Atherosclerotic lesions in HGPS usually exhibit calcification and signs of plaque erosion or rupture, similar to what happens in normal aging [6]. The severity of atherosclerosis in progeria typically correlates with the loss of medial vascular smooth muscle cells (VSMCs), an event that coincides with increased extracellular matrix (ECM) deposition and altered elastin structure [6–8]. HGPS arteries and veins also show pronounced thickening of the adventitia, and this, together with the VSMC loss and excessive ECM accumulation, can result in vessel stiffening and reduced vascular compliance [6]. Furthermore, HGPS patients show age-related defects in cardiac conduction, manifested as prolonged QT interval, ST segment depression/elevation, and negative or biphasic T waves on electrocardiography (ECG) [4,9]. Interestingly, although they exhibit accelerated atherosclerosis, most HGPS patients lack typical cardiovascular risk factors, such as hypercholesterolemia and increased serum C-reactive protein [10]. Thus, progeria provides a model of cardiovascular aging isolated from classical cardiovascular risk factors and can enhance our understanding of vascular stiffening, atherosclerosis, and downstream cardiovascular events such as myocardial infarction and stroke [11,12].

Genetic and molecular mechanisms causing HGPS

Although HGPS was first described at the end of the 19th century [1,2], the cause of the disease remained elusive until 2003, when Eriksson et al. [13] and De Sandre-Giovannoli et al. [14] reported that HGPS patients carry a heterozygous de novo point mutation in the LMNA gene. LMNA encodes A-type lamins, which are nuclear envelope proteins involved in maintaining nuclear structure and function [15]. The two major A-type lamin variants are lamin A and lamin C and arise from alternative splicing of LMNA mRNA [16]. Unlike lamin C, lamin A is formed through several posttranslational modifications of its precursor form, prelamin A. First, the CaaX motif located at the C-terminus is farnesylated [17,18]. Next, the last three residues are removed, and the newly exposed C-terminal cysteine is carboxymethylated [18]. Finally, the zinc metallopeptidase STE24 (ZMPSTE24) cleaves the last 15 amino acids, together with the farnesyl and carboxymethyl groups, resulting in mature lamin A [19–21].

HGPS is typically caused by a cytosine-to-thymine substitution in exon 11 of LMNA (c.1824C>T; p.G608G); this mutation does not affect the encoded amino acid but instead activates a cryptic splice site, leading to aberrant splicing between exons 11 and 12 [13,14]. The resulting mRNA is 150 nucleotides shorter than native LMNA mRNA, and results in the expression of progerin, a truncated form of lamin A that lacks 50 amino acids, including the cleavage site for ZMPSTE24 near the C-terminus. Progerin therefore remains permanently farnesylated and carboxymethylated. Because of the continued presence of the farnesyl group, progerin, unlike lamin A, stays permanently anchored in the inner nuclear membrane and leads to abnormalities in nuclear shape and function [22,23]. Since lamin A is involved in numerous cellular processes, progerin expression has effects on a wide range of functions, including gene expression, signal transduction, heterochromatin organization, cell cycle, and DNA repair [15, 24].

An atherosclerosis-susceptible mouse model with ubiquitous progerin expression

Several progerin-expressing mouse models have been generated for the study of HGPS, including G608G BAC mice [25], LmnaHG/HG mice [26,27], and LmnaG609G/G609G mice [28,29]. HGPS has also been studied in prelamin A-expressing Zmpste24-/- mice [20,30], whose phenotype closely resembles type B mandibuloacral dysplasia [31]. The phenotypes of these mice are diverse, probably reflecting the different gene modification strategies used, which result in varying levels of progerin (or prelamin A), as well as the presence or absence of other Lmna gene products. Among these models, the LmnaG609G/G609G knock-in mice generated by Osorio et al. [28] carry a point mutation in the Lmna gene (c.1827C>T; p.G609G); as occurs in HGPS patients, this mutation leads to the production of progerin via aberrant splicing. Homozygous LmnaG609G/G609G mice show growth retardation, loss of subcutaneous fat, attrition of hair follicles, bone alterations, and a shortened lifespan (a mean of 4 months, versus more than 2 years in wild-type controls) [28]. Notably, these mice present moderate VSMC depletion in the medial layer of the aortic arch, bradycardia, and alterations in cardiac electrical conduction. However, like other HGPS models, LmnaG609G/G609G mice do not develop atherosclerosis, even when fed a high-fat diet [32]. This is in line with numerous studies showing that mice are relatively resistant to atherosclerosis due to profound differences versus humans in their lipid profile; mice have high levels of anti-atherosclerotic high-density lipoproteins (HDLs) and low levels of the pro-atherosclerotic low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs) [33]. Atherosclerosis development in mice therefore usually requires genetic manipulation to alter lipid metabolism, often in combination with the use of western-type diets enriched in cholesterol and saturated fat.

One of the most commonly-used mouse models of atherosclerosis is the Apoe knockout [34–36]. The Apoe gene encodes apolipoprotein E (Apo-E), a key component of plasma lipoproteins, including chylomicrons, VLDLs, and HDLs [37,38]. Apo-E is an important ligand for lipoprotein uptake by hepatocytes. Most circulating Apo-E is produced in the liver, but considerable amounts are also synthesized in the brain, kidneys, adipocytes, and macrophages [39–42]. Defective lipoprotein clearance in Apoe-deficient mice results in elevated plasma levels of atherogenic lipoproteins. These mice therefore develop atherosclerosis on a standard chow diet, and the disease is more severe when the animals are fed western-type high-fat diets [43,44]. Nevertheless, these mice rarely develop the complications observed in human atherosclerosis, such as plaque rupture and ensuing myocardial infarction or stroke.

To generate a model for the study of atherosclerosis in the context of progeria, we crossed LmnaG609G mice with Apoe-deficient mice [32]. As anticipated, Apoe-/-LmnaG609G/G609G mice with ubiquitous progerin expression showed signs of premature aging and had lower body weight and survival than Apoe-/- littermates expressing wild-type lamin A/C. Importantly, Apoe-/-LmnaG609G/G609G mice exhibited accelerated atherosclerosis development in the aorta. The increase in lesion formation was more prominent in older mice, fat-fed mice, and, remarkably, in the thoracic aorta, the aortic region usually least prone to atherosclerosis. Fat-fed Apoe-/-LmnaG609G/G609G mice presented exacerbated lipid accumulation in areas of the aortic media that were typically devoid of VSMCs and rich in ECM, including regions of the media without neighboring atherosclerotic plaques. Aortas of Apoe-/-LmnaG609G/G609G mice also had a thickened and dense adventitial layer, a hallmark of vascular disease in HGPS patients [6]. Notably, atherosclerotic lesions in Apoe-/-LmnaG609G/G609G mice presented vulnerable plaque features, such as large necrotic cores, presence of erythrocytes and iron deposits, and reduced VSMC content in the fibrous cap. Additional cardiovascular alterations in Apoe-/-LmnaG609G/G609G animals included bradycardia, prolonged QRS, QT, and QTc intervals, and an elevated incidence of arrhythmias. The Apoe-/-LmnaG609G/G609G mice thus featured many of the cardiovascular alterations observed in HGPS and, similarly to patients, showed no serum cholesterol elevation versus control Apoe-/- mice.

An atherosclerosis-susceptible mouse model with VSMC-specific progerin expression

Atherosclerosis is a disease of the arteries that leads to their hardening and narrowing with age [12,45]. The disease is usually initiated by LDL accumulation in the arterial wall, causing endothelial cell (EC) dysfunction and leukocyte recruitment to the inflamed site [46]. Recruited monocytes differentiate into macrophages, which upon ingesting LDLs convert into foam cells that secrete pro-inflammatory molecules and attract more immune cells to the growing atherosclerotic lesion. Failure to process the ingested lipoproteins can result in foam cell death and accumulation of debris and cholesterol crystals in the intima, leading to the formation of a necrotic core. Signaling from the growing intima induces phenotypic changes in VSMCs and causes their proliferation and migration from the media to the intima [47]. VSMCs typically migrate towards the subendothelial space to form a fibrous cap, which protects the plaque from rupture and prevents exposure of pro-thrombotic necrotic core constituents to the blood.

Given the central role of ECs, leukocytes, and VSMCs in atherosclerosis development during normal aging, we reasoned that these cell types might contribute to progerin-driven premature atherosclerosis. Analysis of human and mouse HGPS arterial tissue identified VSMCs and, to a lesser extent, macrophages as possible contributors to accelerated atherosclerosis [6,32]. We therefore developed mouse models in which progerin expression was restricted to either VSMCs (Apoe-/-LmnaLCS/LCSSM22αCre) or macrophages (Apoe-/-LmnaLCS/LCSLysMCre) [32]. To generate cell-type–specific HGPS mice, we used a knock-in LmnaLCS/LCS (Lamin C-Stop) model, which expresses only lamin C [28]. When crossed with a Cre-expressing line, LmnaLCS/LCS mice express progerin and lamin C (and a residual level of lamin A) in the tissue or cell type of interest. The phenotype of LmnaLCS/LCS mice is mild, including slightly higher body weight and longer survival than wild-type mice with normal lamin A/C expression [48]. We also observed a non-statistically significant trend toward protection against atherosclerosis in atherosclerosis-prone Apoe-/-LmnaLCS/LCS mice compared with Apoe-/- controls [32].

VSMC- and macrophage-specific progeroid mouse models appeared normal at birth and showed no overt aging phenotype. However, the Apoe-/-LmnaLCS/LCSSM22αCre mice stopped gaining weight at around 5 months of age and died suddenly between 6.5 and 16.5 months of age, whereas the Apoe-/-LmnaLCS/LCSLysMCre mice had normal body weight throughout life and a normal lifespan. Compared with control Apoe-/-LmnaLCS/LCS mice, fat-fed Apoe-/-LmnaLCS/LCSSM22αCre mice (but not Apoe-/-LmnaLCS/LCSLysMCre mice) had a higher atherosclerosis burden and aortic structural alterations (VSMC loss, adventitial thickening, and lipid accumulation in the media). Moreover, atherosclerotic plaques in Apoe-/-LmnaLCS/LCSSM22αCre mice had vulnerable features, thus fully recapitulating the vascular disease observed in the ubiquitous progeria model. Remarkably, all these vascular pathologies were independent of the elevated serum cholesterol, which was indistinguishable from the level in Apoe-/-LmnaLCS/LCS mice. Unlike Apoe-/-LmnaG609G/G609G mice, Apoe-/-LmnaLCS/LCSSM22αCre mice presented no ECG alterations at 4 months of age, consistent with the VSMC-specificity of the model.

Cause of death in progeria mouse models

Although the ubiquitous and VSMC-specific progeroid models had the same vascular phenotype, Apoe-/-LmnaLCS/LCSSM22αCre mice showed none of the premature aging features and cardiac alterations observed in Apoe-/-LmnaG609G/G609G mice (Table 1) [32]. Moreover, while both models had a shortened lifespan, survival of Apoe-/-LmnaLCS/LCSSM22αCre mice was almost double that of Apoe-/-LmnaG609G/G609G mice. Insight into the cause of death in these animals was gained by further comparison between atherosclerosis-prone progeroid mice (Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre) and atheroresistant progeroid mice with an intact Apoe gene (LmnaG609G/G609G and LmnaLCS/LCSSM22αCre). Survival was similar in atherosclerosis-prone Apoe-/-LmnaG609G/G609G mice and atherosclerosis-free LmnaG609G/G609G mice, suggesting that the cause of death is the same in both models and is independent of atherosclerosis. In contrast, whereas lifespan in atherosclerosis-free LmnaLCS/LCSSM22αCre mice was the same as in control mice, atherosclerosis-prone Apoe-/-LmnaLCS/LCSSM22αCre mice died prematurely. These findings suggest that atherosclerosis underlies death in Apoe-/-LmnaLCS/LCSSM22αCre mice but not in Apoe-/-LmnaG609G/G609G mice. Histopathological analysis of aorta and heart samples from both models confirmed that the stage of CVD in mice close to maximum lifespan is compatible with death from atherosclerosis-related causes in Apoe-/-LmnaLCS/LCSSM22αCre mice but not in Apoe-/-LmnaG609G/G609G mice. Thus, death in Apoe-/-LmnaG609G/G609G mice is likely due to other disease symptoms arising before atherosclerosis becomes a life-threatening symptom, such as arrhythmias, cachexia, and starvation [9,49]. In ubiquitous progeria mice, progerin is expressed in most differentiated cells (following the pattern of lamin A expression); consequently, CVD development and premature aging and death in these animals likely involve contributions from many cell types, including cardiomyocytes, fibroblasts, ECs, and VSMCs. Supporting this view, Osmanagic-Myers et al. recently reported that transgenic mice with EC-specific progerin expression present myocardial fibrosis associated with left ventricular hypertrophy and diastolic dysfunction [50], cardiac pathologies that may also be involved in premature death in progeria.

Table 1.

Comparison of phenotypic features between atherosclerosis-prone mouse models with ubiquitous and vascular smooth muscle cell-specific progerin expression.

Feature Apoe-/-LmnaG609G/G609G Apoe-/-LmnaLCS/LCSSM22αCre  
Appear aged yes no Aging phenotype and lifespan
Shortened lifespan yes (median survival ≈18 weeks) yes (median survival ≈34 weeks)  
Thickened adventitia yes yes Vascular phenotype
(at 16 weeks of age on a high-fat diet and, to a lesser extent, on normal chow diet)
VSMC loss in the media yes yes
Lipid retention in the media yes yes
Increased atherosclerosis yes yes
Vulnerable plaque features yes yes
Bradycardia yes no Cardiac phenotype
(at 16 weeks of age on normal chow diet)
Arrhythmia yes no
Prolonged QRS, QT, QTc yes no
Open in a new tab

Even though the principal cause of death in Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice is different, both models showed evidence of plaque disruption and myocardial infarction [32], complications rarely seen in mice but typical of late stages of atherosclerosis in HGPS and non-HGPS individuals. These findings, together with the VSMC loss and adventitial thickening observed in these mice, demonstrate that Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre models faithfully model the vascular disease found in HGPS patients.

How does progerin expression in VSMCs accelerate atherosclerosis?

Studies with Apoe-/-LmnaLCS/LCSSM22αCre mice have demonstrated that progerin expression in VSMCs is sufficient to cause progressive loss of these cells and accelerate atherosclerotic disease in the absence of cholesterol elevation relative to Apoe-/-LmnaLCS/LCS control mice [32]. Progerin-triggered VSMC death was accompanied by excessive lipid accumulation in the aortic wall, suggesting that increased retention of atherogenic LDLs may account, at least in part, for the early onset of atherosclerosis in Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice. Experiments with 16-week-old mice fed normal chow and injected with fluorescently-labelled LDLs showed enhanced LDL retention in the aortic wall in both the ubiquitous and the VSMC-specific progeroid models. At this age, aortas of Apoe-/-LmnaG609G/G609G and Apoe-/-LmnaLCS/LCSSM22αCre mice show moderate loss of VSMCs and their replacement by ECM, suggesting that increased ECM content or altered ECM composition promotes LDL retention. However, it remains to be determined whether premature atherosclerosis in HGPS also involves contributions from other factors, such as increased endothelial permeability resulting from endothelial dysfunction.

Concluding remarks

Apoe-/- mice with ubiquitous and VSMC-specific progerin expression offer a unique opportunity to study atherosclerosis in the setting of progeria. Apoe-/-LmnaG609G/G609G mice, which show both a premature aging phenotype and accelerated CVD, permit the study of progeria features in a broader context. Conversely, Apoe-/-LmnaLCS/LCSSM22αCre mice allow investigation of progerin-induced vascular disease, including atherosclerosis, in isolation from other premature aging symptoms. Moreover, these models can aid in the understanding of physiological aging [11,12], since small amounts of progerin are also produced in the cells of normally-aging non-HGPS individuals [6,51,52]. Given that the expression of progerin in VSMCs plays a crucial role in accelerated atherosclerosis and premature death in Apoe-/- mice, further efforts are warranted to reveal the mechanisms underlying VSMC loss in HGPS. These studies may also shed light on progeria-unrelated diseases characterized by VSMC loss, such as aneurysm formation.

Funding Statement

M.R.H. is supported by a ‘Juan de la Cierva’ postdoctoral fellowship (FJCI-2017-33299) from the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU). Work in V.A.’s laboratory is supported by grants from the Spanish Instituto de Salud Carlos III (AC16/00091 and AC17/00067) and MCIU (SAF2016-79490-R), with co-funding from the Fondo Europeo de Desarrollo Regional (FEDER, ‘Una manera de hacer Europa’), the Progeria Research Foundation (Established Investigator Award 2014-52), and the Fundació Marató TV3 (122/C/2015). The CNIC is supported by the MCIU and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505); Instituto de Salud Carlos III [AC16/00091 and AC17/00067]; MCIU [SAF2016-79490-R]; MCIU [FJCI-2017-33299]; MCIU [SEV-2015-0505]; Progeria Research Foundation [2014-52].

Acknowledgments

We thank Simon Bartlett for English editing.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

  • [1].Hutchinson J. Congenital absence of hair and mammary glands with atrophic condition of the skin and its appendages, in a boy whose mother had been almost wholly bald from alopecia areata from the age of six. Med Chir Trans. 1886;69:473–477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Gilford H. On a condition of mixed premature and immature development. Med Chir Trans. 1897;80:17–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006;140(23):2603–2624. [DOI] [PubMed] [Google Scholar]
  • [4].Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358(6):592–604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015;132:249–264. [DOI] [PubMed] [Google Scholar]
  • [6].Olive M, Harten I, Mitchell R, et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010;30(11):2301–2309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Stehbens WE, Wakefield SJ, Gilbert-Barness E, et al. Histological and ultrastructural features of atherosclerosis in progeria. Cardiovasc Pathol. 1999;8(1):29–39. [DOI] [PubMed] [Google Scholar]
  • [8].Stehbens WE, Delahunt B, Shozawa T, et al. Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc Pathol. 2001;10(5):235–240. [DOI] [PubMed] [Google Scholar]
  • [9].Rivera-Torres J, Calvo CJ, Llach A, et al. Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Proc Natl Acad Sci USA. 2016;113(46):E7250–E7259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Gordon LB, Harten IA, Patti ME, et al. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J Pediatr. 2005;146(3):336–341. [DOI] [PubMed] [Google Scholar]
  • [11].Gordon LB, Rothman FG, López-Otín C, et al. Progeria: a paradigm for translational medicine. Cell. 2014;156(3):400–407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Hamczyk MR, Del Campo L, Andrés V. Aging in the cardiovascular system: lessons from Hutchinson-Gilford progeria syndrome. Annu Rev Physiol. 2018;80:27–48. [DOI] [PubMed] [Google Scholar]
  • [13].Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423(6937):293–298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055. [DOI] [PubMed] [Google Scholar]
  • [15].Andrés V, González JM. Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol. 2009;187(7):945–957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 1993;268(22):16321–16326. [PubMed] [Google Scholar]
  • [17].Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol. 1990;110(5):1489–1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Sinensky M, Fantle K, Trujillo M, et al. The processing pathway of prelamin A. J Cell Sci. 1994;107(Pt 1):61–67. [DOI] [PubMed] [Google Scholar]
  • [19].Corrigan DP, Kuszczak D, Rusinol A, et al. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J. 2005;387(1):129–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Pendás AM, Zhou Z, Cadiñanos J, et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet. 2002;31(1):94–99. [DOI] [PubMed] [Google Scholar]
  • [21].Weber K, Plessmann U, Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett. 1989;257(2):411–414. [DOI] [PubMed] [Google Scholar]
  • [22].Vidak S, Foisner R. Molecular insights into the premature aging disease progeria. Histochem Cell Biol. 2016;145(4):401–417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Gonzalo S, Kreienkamp R, Askjaer P. Hutchinson-Gilford progeria syndrome: A premature aging disease caused by LMNA gene mutations. Ageing Res Rev. 2017;33:18–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Dorado B, Andrés V. A-type lamins and cardiovascular disease in premature aging syndromes. Curr Opin Cell Biol. 2017;46:17–25. [DOI] [PubMed] [Google Scholar]
  • [25].Varga R, Eriksson M, Erdos MR, et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Nat Acad Sci USA. 2006;103(9):3250–3255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Yang SH, Bergo MO, Toth JI, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Nat Acad Sci USA. 2005;102(29):10291–10296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Yang SH, Meta M, Qiao X, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest. 2006;116(8):2115–2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Osorio FG, Navarro CL, Cadiñanos J, et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011;3(106):106ra107. [DOI] [PubMed] [Google Scholar]
  • [29].Lee JM, Nobumori C, Tu Y, et al. Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J Clin Investig. 2016;126(4):1592–1602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Bergo MO, Gavino B, Ross J, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Nat Acad Sci USA. 2002;99(20):13049–13054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Ben Yaou R, Navarro C, Quijano-Roy S, et al. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation. Eur J Hum Genet. 2011;19(6):647–654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Hamczyk MR, Villa-Bellosta R, Gonzalo P, et al. Vascular smooth muscle-specific progerin expression accelerates atherosclerosis and death in a mouse model of Hutchinson-Gilford progeria syndrome. Circulation. 2018;138(3):266–282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Yin W, Carballo-Jane E, McLaren DG, et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res. 2012;53(1):51–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343–353. [DOI] [PubMed] [Google Scholar]
  • [35].Piedrahita JA, Zhang SH, Hagaman JR, et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Nat Acad Sci USA. 1992;89(10):4471–4475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr. 1995;15:495–518. [DOI] [PubMed] [Google Scholar]
  • [37].Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–630. [DOI] [PubMed] [Google Scholar]
  • [38].Ang LS, Cruz RP, Hendel A, et al. Apolipoprotein E, an important player in longevity and age-related diseases. Exp Gerontol. 2008;43(7):615–622. [DOI] [PubMed] [Google Scholar]
  • [39].Williams DL, Dawson PA, Newman TC, et al. Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J Biol Chem. 1985;260(4):2444–2451. [PubMed] [Google Scholar]
  • [40].Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res. 2009;50(Suppl):p. S156–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Basu SK, Ho YK, Brown MS, et al. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem. 1982;257(16):9788–9795. [PubMed] [Google Scholar]
  • [42].Werb Z, Chin JR, Takemura R, et al. The cell and molecular biology of apolipoprotein E synthesis by macrophages. Ciba Found Symp. 1986;118:155–171. [DOI] [PubMed] [Google Scholar]
  • [43].Fuster JJ, Castillo AI, Zaragoza C, et al. Animal models of atherosclerosis. Prog Mol Biol Transl Sci. 2012;105:1–23. [DOI] [PubMed] [Google Scholar]
  • [44].Getz GS, Reardon CA. Use of mouse models in atherosclerosis research. Methods Mol Biol. 2015;1339:1–16. [DOI] [PubMed] [Google Scholar]
  • [45].Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13(2):79–98. [DOI] [PubMed] [Google Scholar]
  • [46].Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015;116(2):307–311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47].Fuster JJ, Fernández P, González-Navarro H, et al. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardiovasc Res. 2010;86(2):254–264. [DOI] [PubMed] [Google Scholar]
  • [48].Lopez-Mejia IC, de Toledo M, Chavey C, et al. Antagonistic functions of LMNA isoforms in energy expenditure and lifespan. EMBO Rep. 2014;15(5):529–539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Kreienkamp R, Billon C, Bedia‐Diaz G, et al. Doubled lifespan and patient-like pathologies in progeria mice fed high-fat diet. Aging Cell. 2018;e12852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Osmanagic-Myers S,  Kiss A, Manakanatas C, et al. Endothelial progerin expression causes cardiovascular pathology through an impaired mechanoresponse. J Clin Investig. 2019;129:531–545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [51].Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312(5776):1059–1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].McClintock D, Ratner D, Lokuge M, et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One. 2007;2(12):e1269. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nucleus are provided here courtesy of Taylor & Francis

RESOURCES